Xience Registry In Complex Lesion of Acute Coronary Syndrome Patients witH Ticagrelor (RICH)
NCT ID: NCT05746416
Last Updated: 2023-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
977 participants
OBSERVATIONAL
2019-01-02
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer are:
Given the low ischemic risk and high bleeding tendency in Asians, the low dose TDAPT may provide better net clinical benefits of ischemic and bleeding events than the standard dose TDAPT.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation
NCT04331145
Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation
NCT05758909
Safety and Performance Study of the Optimum Transcatheter Aortic Valve
NCT04076150
A Study to Obtain Imaging Data in 40 Patients Having Transcatheter Aortic Valve Implantation (TAVI)
NCT06596460
Cardioprotective Effect of RIPC in Patients Undergoing TAVI
NCT02283398
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Successful PCI was defined as a residual stenosis \<30% with Thrombolysis in Myocardial Infarction grade 3 flow after PCI and the absence of death by MI and reintervention for the index coronary lesions during the admission period. Standard definitions of cardiovascular events were used for all clinical events. Myocardial infarction (MI) was defined using the 4th universal definition of MI as previously described. Repeat revascularization (RR) was defined as a new PCI for the target vessels or de-novo coronary lesions. All-cause death was defined as a death from any cause. Cardiovascular death was defined as death from MI, stent thrombosis and ischemic stroke. A major adverse cardiac and cerebrovascular event (MACE) was defined as a composite of cardiovascular death, non-fetal MI, RR, stent thrombosis and ischemic stroke. A bleeding event was defined as the bleeding event equivalent to Bleeding Academic Research Consortium (BARC) classification 2 or higher. A net clinical event (NCE) was defined as a composite of MACEs and bleeding events. Patients were scheduled to follow up to 2 years after index PCI. Clinical follow-up started when a patient discharged from the hospitalization for the index PCI and ended when the patient experienced the any clinical event or reached the end of follow-up. The follow-up visits were scheduled at 1, 3 and 6 months, 1 year and 2 years after discharge.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
s-TDAPT group
Ticagrelor 180mg + Aspirin 100mg within 6 months after index PCI
No interventions assigned to this group
l-TDAPT group
Ticagrelor 120mg + Aspirin 100mg within 6 months after index PCI
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* acute coronary syndrome (ACS) undergoing PCI
* PCI for complex coronary lesions using everolimus-eluting stents (Xience®, Abbot corp, Chicago, Illinois, US)
* prescribed with s-TDAPT for more than 3 months
Exclusion Criteria
* PCI using drug-eluting stents (DES) other than the everolimus-eluting stents
* those who had conditions requiring a long-term oral anticoagulant therapy
* those with life expectancy \<1 year
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Soon Chun Hyang University
OTHER
Abbott
INDUSTRY
Hanyang University Seoul Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Young-Hyo Lim
professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Young-Hyo Lim
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RICH_2020-0104
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.